Drug Formulary Review Archives – December 1, 2007
December 1, 2007
View Archives Issues
-
Multidisciplinary clinic with pharmacist improves care
Can a multidisciplinary diabetes management clinic that includes a pharmacist improve care for patients with Type 2 diabetes mellitus? The answer is a resounding yes, according to Erin Newkirk, PharmD, of the University of Iowa Hospitals and Clinics. -
Antidote triggers find unreported ADRs
Research at the University of Pittsburgh has shown that tracking adult ICU use of antidotes such as protamine and phytonadione can signal adverse drug reactions (ADRs). A report on the study was given at the recent American College of Clinical Pharmacists meeting. -
Hospitals told how to ease high-alert problems
A report in the Joint Commission Journal on Quality and Healthcare Safety makes recommendations for hospitals to follow to reduce patient harm related to high-alert medications. -
Prescribing changes as patients near death
A study intended to determine how prescribing for comorbid illnesses and symptom control changes during the palliative phase of a terminal illness found older people take more medications and says medications for comorbid conditions should be reviewed in the context of their original therapeutic goals. -
Robot works for patient safety at Nebraska Medical
The newest employee in the remodeled inpatient pharmacy at the Nebraska Medical Center in Omaha is eight feet tall and 36 feet wide and is capable of storing 44,000 medication unit doses. -
News Briefs
First responders helped by inhaled corticosteroids; FDA expands age range for Menactra use; Change in Humate-P storage approved -
Drug Criteria & Outcomes: Phosphate laxatives: The renal risk
Oral sodium phosphate (OSP) products are commonly used for bowel cleansing, but many health care professionals are not aware of a serious adverse effect associated with these drugs. -
Drug Criteria & Outcomes: New FDA Approvals
FDA recently announced these approvals: The first generic versions of Novartis' anticonvulsant Trileptal® (oxcarbazepine) have been approved by FDA for use alone or in combination with other medications in treating partial seizures in adults and children ages four and older.